{"id":99900,"date":"2025-10-14T09:15:07","date_gmt":"2025-10-14T09:15:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/abalos-therapeutics-publishes-in-cell-reports-medicine-validating-abx-001s-potential-to-overcome-cancer-immunotherapy-hurdles\/"},"modified":"2025-10-14T09:15:07","modified_gmt":"2025-10-14T09:15:07","slug":"abalos-therapeutics-publishes-in-cell-reports-medicine-validating-abx-001s-potential-to-overcome-cancer-immunotherapy-hurdles","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/abalos-therapeutics-publishes-in-cell-reports-medicine-validating-abx-001s-potential-to-overcome-cancer-immunotherapy-hurdles\/","title":{"rendered":"Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001\u2019s Potential to Overcome Cancer Immunotherapy Hurdles"},"content":{"rendered":"
\n

— Preclinical data support Abalos\u2019 first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors —\u00a0<\/i>
\u00a0<\/b>\u00a0<\/b><\/p>\n

D\u00fcsseldorf, Germany, October 14, 2025<\/b> \u2013 Abalos Therapeutics<\/a> announced today the publication of preclinical proof-of-concept data for the company\u2019s immunoactivating lead candidate, ABX-001, in Cell Reports Medicine,<\/i> highlighting its potential as a powerful new drug class in cancer treatment. Through ABX-001\u2019s capability to systemically activate both innate (immediate) and adaptive (memory) immune responses with a single administration, Abalos aims to reach new levels of immune system engagement and address current limitations in immunotherapy. <\/p>\n

The publication titled \u201cOptimized arenavirus design with tumor-tropic mutations promote safety and anti-tumor efficacy via sustainable immune modulatory properties\u201d provides a comprehensive overview of the development and evaluation of ABX-001, the first drug candidate leveraging Abalos\u2019 proprietary AdaptInnate<\/i> approach. Abalos developed ABX-001 as therapeutic candidate by optimizing a non-lytic arenavirus strain using strategic selections of specific mutations for immunostimulatory and anti-tumoral properties, including high tumor-tropism and minimal replication in healthy cells. Importantly, ABX-001\u2019s mode of action is characterized by persistent and sustained replication in cancerous as well as antigen-presenting cells without destroying them. This results in exceptional induction of effector T-cells and actively guides immune cells into the tumor. This novel, non-oncolytic approach for systemic use is designed to induce a targeted, effective, and durable anti-cancer activity against primary tumors and tumor cells that have migrated to other regions of the body, so called metastases.<\/p>\n

\u201cThe publication in Cell Reports<\/i> Medicine<\/i> underscores the potential of our novel anti-cancer approach as a promising alternative for patients who face the limitations of current immunotherapies,\u201d said J\u00f6rg Vollmer, CSO at Abalos. \u201cBy safely engaging all major lymphatic organs in a coordinated, body-wide attack against tumors, we aim to overcome key challenges such as immune evasion of cancer cells, inadequate T cell activation, and tumor heterogeneity. The strong safety profile and robust anti-cancer activity demonstrated across a range of clinically relevant solid tumor models provide a solid foundation for the clinical development of ABX-001, with the first-in-human trial expected to begin soon.\u201d<\/p>\n

In a variety of murine solid tumor models, ABX-001 exhibited strong anti-tumoral efficacy by inducing the expansion of tumor-specific T cells and immune-activating cytokines such as IFN-\u03b3. Notably, mice with complete tumor remission upon systemic ABX-001 treatment were protected from tumor cell re-challenge, suggesting long-lasting anti-tumoral immunity. The candidate demonstrated a favorable safety profile, with minimal viral replication in healthy tissues and no severe disease symptoms in arenavirus-susceptible mice. The results were replicated in non-human primates highly sensitive to wildtype arenaviruses. Here, treatment with ABX-001 led to substantially increased levels of immunostimulatory cytokines and chemokines as well as significantly increased expansion of monocytes, CD4+<\/sup> and CD8+<\/sup> T cells. The CD4+<\/sup>\/CD8+<\/sup> ratio decreased after ABX-001 application, reflecting the strong priming of cytotoxic T cells triggered by the candidate. Despite this strong immune activation, no adverse effects were observed at any dose level or timepoint, demonstrating a highly favorable safety profile.<\/p>\n

Data on the development of ABX-001 and its demonstrated proprietary anti-tumoral efficacy in a range of in vitro<\/i> and in vivo <\/i>models will be presented at the European Society for Medical Oncology (ESMO) Congress 2025. <\/p>\n

Presentation Details:<\/b><\/p>\n

Poster presentation<\/b>
Abstract Title:<\/b> Optimized arenavirus design with tumor-tropic mutations accelerates anti-tumor efficacy of lymphocytic choriomeningitis sustainable immune modulatory properties
Date: <\/b>Monday, October 20, 2025
Presenter: <\/b>Prof. Karl S Lang, PhD, Chair of Immunology at the Medical Faculty, University Duisburg-Essen and Scientific Founder of Abalos
Location: <\/b>Poster Session 2, Hall 25, Messe Berlin, Germany
Poster Number:<\/b> #342<\/p>\n

Based on the encouraging preclinical proof-of-concept data, Abalos is advancing ABX-001 into a Phase 1 first-in-human basket-style trial across sites in Europe.<\/p>\n

About Abalos Therapeutics<\/b>
Abalos Therapeutics is pioneering a novel anti-cancer approach that directs the full breadth of the immune system\u2019s power specifically towards cancer cells. Abalos\u2019 arenavirus-based drug candidates are designed to trigger precise innate and adaptive immune responses from within the tumor to engage all relevant immune cell types in a concerted attack against both the primary tumor and distant metastases. The company\u2019s lead product candidate ABX-001 has demonstrated strong anti-tumor efficacy in pre-clinical studies in multiple tumor models as well as an excellent pre-clinical safety profile and will enter the clinic in 2025. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos\u2019 goal is to establish a new drug class in immuno-oncology. For more information, please visit www.abalos-tx.com<\/a>. <\/p>\n

For more information, please contact:<\/b><\/p>\n

Abalos Therapeutics GmbH<\/b>
Phone: +49 211 540104-0
Email: info@abalos-tx.com<\/a> <\/p>\n

Abalos media inquiries<\/b>
Trophic Communications
Stephanie May \/ Marie-Theresa Weickert
Phone: +49 171 185 56 82
Email: abalos@trophic.eu<\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

— Preclinical data support Abalos\u2019 first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors —\u00a0\u00a0\u00a0 D\u00fcsseldorf, Germany, October 14, 2025 \u2013 Abalos Therapeutics announced today the publication of preclinical proof-of-concept data for the company\u2019s immunoactivating lead candidate, ABX-001, in Cell Reports Medicine, highlighting its potential as a powerful […]<\/p>\n","protected":false},"author":2,"featured_media":99901,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1c37d6d1-057d-4724-8568-93f1cadc1a86","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-99900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t